Sfoglia per AUTORE
TOGNON G
Collezione AO Ordine Mauriziano

  

Items : 5

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.
2024
AO Ordine Mauriziano
AOU Città della Salute di Torino

Barretina Ginesta MP; Uggeri S; Rulli E; Laudani ME; Lissoni AA; Petrella M; Tognon G; Ferrero A; Manso L; Takehara K; Tasca G; Zamagni C; McQueen J; Nakagawa S; Piovano E; Pardo B; Lee YC; Nishio S; Allan K; Fariñas-Madrid L; Parma G; Marth C; Marmé F; Rabaglio M; Antill Y; Choi CH; Hudson E; Galli F; Harano K; et alii...

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5.
2024
AO Ordine Mauriziano

Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G;

Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial. in The International journal of biological markers / Int J Biol Markers. 2024 Dec;39(4):328-337. doi: 10.1177/03936155241296164. Epub 2024 Nov 8.
2024
AO Ordine Mauriziano

Indraccolo S; Signoriello S; Piga I; Esposito G; Ferrarini F; Boscolo Bragadin A; Salutari V; Pisano C; Califano D; Bignotti E; Tognon G; Simeon V; Artioli G; Ferrero A; Cinieri S; Bologna A; Chiodini P; Scognamiglio G; Bottoni C; Spina A; Russo D; Arenare L; Perrone F; Pignata S;

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30.
2021
AO Ordine Mauriziano

Gallo C; Schettino C; Gargiulo P; Greggi S; Distefano M; Bogani G; Nardin M; Lapresa M; Cecere SC; Salutari V; Lorusso D; Katsaros D; Lissoni AA; Scollo P; De Giorgi U; Cinieri S; De Censi A; Breda E; Ferrero A; Lauria R; Gadducci A; Tognon G; Artioli G; Frezzini S; Colombo N; Pisano C; Scambia G; Raspagliesi F; Arenare L; et alii...

2019
AO Ordine Mauriziano

Colombo N; Zaccarelli E; Baldoni A; Frezzini S; Scambia G; Palluzzi E; Tognon G; Lissoni AA; Rubino D; Ferrero A; Farina G; Negri E; Pesenti Gritti A; Galli F; Biagioli E; Rulli E; Poli D; Gerardi C; Torri V; Fossati R; D'Incalci M;